TickerTalks
Browse all tickers →
TickerTalks›$KALA
KAKALA

KALA BIO, Inc.

$KALA·$15M·Biotechnology·Healthcare
$0.74-5.1%YTD-97.4%1Y-99.8%
Mentions · last 7 days
2026-07-28: 7 posts2026-07-29: 5 posts2026-07-30: 14 posts2026-07-31: 15 posts2026-08-01: 10 posts2026-08-02: 6 posts2026-08-03: 5 posts62+4%
Price updated 2h ago·X counts updated 1d ago
KAKALA
$KALAKALA BIO, Inc.
$0.74-5.11%62 posts+4%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $KALA, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storySelling offAI verdict · as of 2026-08-04

Falling on heavy selling — points lower unless it turns around.

Kala Bio filed a $250M offering at $0.001/share after a 99.8% T12M drawdown and reverse split — a distressed dilution setup into Aug 6 earnings.

Kala Bio is a formerly ophthalmology-focused biotech that has effectively collapsed — 99.8% T12M drawdown, revenue at zero after divestitures, and a distressed capital structure. The July 22 $250M offering at $0.001/share plus the earlier reverse split are the entire near-term story.

  • The $250M offering at $0.001/share is the story-defining event: a live prospectus supplement pricing dilution at effectively zero — the classic pattern of a distressed shell being recapitalized.
  • Zero revenue with negative FCF yield is the fundamental reality: Q1 revenue at $0 with -$0.20 EPS and -33% FCF yield — real operational collapse, and the -$6 EPS pre-earnings estimate reflects an expected large writedown.
  • The May reverse split is context for the extreme decline: reverse splits typically precede delisting risk or capital-raise attempts — the -99.8% T12M measures the post-split reality, and 0.02% of 52w range confirms near-zero technicals.
  • The July 2 SC 13D/A conversion is a subtle insider signal: a Series AA Preferred holder converted 719K shares at $1.82/share — meaningful because it's Preferred-to-common at a price far above the offering, suggesting the person expects structural recovery.

Aug 6 is the tension breaker. Q2 with concrete pipeline plus specific use-of-proceeds for the $250M raise restarts the recovery toward $2; a further liquidation-orientation or a delisting notice and the setup extends sub-$0.50 with the -99.8% T12M as the anchor.

What to watch: Aug 6 Q2 print: watch for use-of-proceeds detail on the $250M raise, any pipeline commentary, going-concern language, and delisting-risk disclosures — the signals that seal or break the distressed setup.

On the calendar: 2026-08-06 — Q2 earnings

thin bundle

Read the AI verdict + X sentiment for $KALA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Ophthalmic biotech using mucus-penetrating nanoparticle (MPP) drug delivery to treat inflammatory eye diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $KALA.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $KALA

Neutral — Ophthalmic biotech using mucus-penetrating nanoparticle (MPP) drug delivery to treat inflammatory eye diseases; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+40.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-282%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-32.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-13.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 15, 2026$-0.20$-8.50+97.6%
Q1 2026Apr 15, 2026$0.08$-16.00+100.5%
Q3 2025Nov 19, 2025$-1.07$-1.01-5.9%
Q2 2025Aug 8, 2025$-1.71$-1.82+6.0%
Next earningsThu, Aug 6·consensus EPS $-6.00

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.20$-2.9M
Q4 FY25$0———$0.08$-4.6M
Q3 FY25$0———$-1.07$-10.9M
Q2 FY25$0———$-1.71$-7.7M

Forward consensus

4-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$25.0M$25.0M – $25.0M-$26.50-$26.50 – -$26.501
FY27$26.1M$26.1M – $26.1M-$20.00-$20.00 – -$20.001
FY28$134.2M$134.2M – $134.2M-$9.00-$9.00 – -$9.001
FY29$229.3M$229.3M – $229.3M-$8.50-$8.50 – -$8.501

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.0%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-57.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-95.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 18.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-2.365-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)Jul 22424B5
AI summary

KALA filed a 424B5 prospectus supplement offering $250M at $0.001/share. This is a live, priced offering representing immediate dilution to existing shareholders. Proceeds are intended for stated in the supplement. Investors should assess the dilutive impact relative to current market cap and cash position.

SC 13D/AActivist amendmentJul 2SC 13D/A
AI summary

An amended SC 13D for KALA BIO discloses the reporting person converted Series AA Preferred Stock (purchased under a prior SPA) into 719,404 common shares at an aggregate cost of $1,308,007, based on 18,589,787 shares outstanding as of June 9, 2026. Post-conversion percentage is not stated in the excerpt. Update to a previously disclosed position following preferred-to-common conversion.

S-3/AShelf registrationJun 12S-3/A
AI summary

Kala Bio (KALA) filed Amendment No. 1 to its Form S-3 shelf registration (Registration No. 333-295667) on June 12, 2026 as a smaller reporting company. This is a routine amendment to an existing shelf filing, typically filed to update financial statements or other disclosure; no new offering terms were specified in the excerpt.

S-3Shelf registrationMay 7S-3
AI summary

Kala Bio (KALA) filed an initial Form S-3 shelf registration statement on May 7, 2026 as a smaller reporting company. The specific aggregate offering amount was not disclosed in the excerpt. This is a routine shelf filing enabling future capital raises.

8-KCharter amendmentMay 78-K — Item 3.03 · Item 5.03: Charter amendment · Item 8.01: Other event
AI summary

Kala Bio (KALA) effected a 1-for-50 reverse stock split, effective May 8, 2026 at 4:05 PM Delaware time. The Certificate of Amendment to the Certificate of Incorporation was filed on May 7, 2026 (Item 5.03). The split also triggered Item 3.03 (material modification to rights of holders) and Item 8.01. Reverse splits at this ratio typically reflect a stock trading at very low prices, potentially to regain or maintain exchange listing compliance.

8-KMaterial agreementMar 48-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale · Item 7.01: Press release / Reg FD
8-KOfficer or director changeFeb 208-K — Item 5.02: Officer or director change
S-3Shelf registrationFeb 10S-3
+ 18 other (5 3s · 2 EFFECTs · 2 13Gs · 2 Ds) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

KALA BIO (KALA) Expected to Post Earnings on Thursdaydefenseworld.net·6d agoKALA BIO Announces Reverse Stock Splitglobenewswire.com·90d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$REPL$REGN$IBRX$CAPR$HALO$AURA$ABCL$MRNA
Voices on X · last 7 days

No standout posts about $KALA on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport